{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:48:39Z","timestamp":1777427319645,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Shanghai Municipal Health and Family Planning Commission Fund Project","award":["Grant No. 201640057"],"award-info":[{"award-number":["Grant No. 201640057"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81770876; 81270011; 81472125"],"award-info":[{"award-number":["Grant No. 81770876; 81270011; 81472125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12890-018-0734-1","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T11:48:29Z","timestamp":1542714509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study"],"prefix":"10.1186","volume":"18","author":[{"given":"Ye","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingdong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"734_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2018.03.013","volume":"119","author":"S Yomo","year":"2018","unstructured":"Yomo S, Oda K. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: a retrospective analysis of 133 consecutive patients. Lung Cancer. 2018;119:120\u20136.","journal-title":"Lung Cancer"},{"issue":"27","key":"734_CR2","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","volume":"34","author":"Y Urata","year":"2016","unstructured":"Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized phase III study comparing Gefitinib with Erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016;34(27):3248.","journal-title":"J Clin Oncol"},{"key":"734_CR3","doi-asserted-by":"crossref","unstructured":"Ostoros G, Sarosi V, Mandoky L, Pinter F, Schwab R, Petak I, et al. Effectiveness of erlotinib in lung adenocarcinomas with classic and alternative EGFR mutations detected by Roche 454 GS-FLX next-generation sequencing (NGS). J Clin Oncol. 2013;31(15).","DOI":"10.1200\/jco.2013.31.15_suppl.e19090"},{"issue":"7","key":"734_CR4","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1200\/JCO.2009.24.0747","volume":"28","author":"CN Lee","year":"2010","unstructured":"Lee CN, Chen HY, Liu HE. Favorable response to Erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. J Clin Oncol. 2010;28(7):E111\u2013E2.","journal-title":"J Clin Oncol"},{"issue":"1","key":"734_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/JTO.0b013e3181f77b27","volume":"6","author":"WC Fan","year":"2011","unstructured":"Fan WC, Yu CJ, Tsai CM, Huang MS, Lai CL, Hsia TC, et al. Different efficacies of Erlotinib and Gefitinib in Taiwanese patients with advanced non-small cell lung Cancer a retrospective multicenter study. J Thorac Oncol. 2011;6(1):148\u201355.","journal-title":"J Thorac Oncol"},{"key":"734_CR6","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Park BJ, Kris MG, Miller VA, Riely GJ, Zheng J, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. J Clin Oncol. 2009;27(15).","DOI":"10.1200\/jco.2009.27.15_suppl.7523"},{"issue":"4","key":"734_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jjco\/hyw206","volume":"47","author":"J Kashima","year":"2017","unstructured":"Kashima J, Okuma Y, Miwa M, Hosomi Y. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib. Jpn J Clin Oncol. 2017;47(4):357\u201362. https:\/\/doi.org\/10.1093\/jjco\/hyw206 .","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"734_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijrobp.2014.02.022","volume":"89","author":"NK Gerber","year":"2014","unstructured":"Gerber NK, Yamada Y, Rimner A, Shi WJ, Riely GJ, Beal K, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;89(2):322\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"734_CR9","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.ijrobp.2012.07.167","volume":"84","author":"H Zhuang","year":"2012","unstructured":"Zhuang H, Yuan Z, Wang J, Zhao L, Wang P. Phase II study of WBRT with or without concurrent Erlotinib for patients with brain metastases from lung adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012;84(3):S102.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"734_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2147\/DDDT.S53011","volume":"7","author":"HQ Zhuang","year":"2013","unstructured":"Zhuang HQ, Yuan ZY, Wang J, Zhao LJ, Pang QS, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Dev Ther. 2013;7:1179\u201386.","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"734_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/JTO.0b013e318202bffe","volume":"6","author":"YY Janjigian","year":"2011","unstructured":"Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, et al. Impact on disease-free survival of adjuvant Erlotinib or Gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011;6(3):569\u201375.","journal-title":"J Thorac Oncol"},{"key":"734_CR12","doi-asserted-by":"crossref","unstructured":"Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, et al. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC Pharmacol Toxicol. 2017;18.","DOI":"10.1186\/s40360-017-0130-0"},{"issue":"12","key":"734_CR13","first-page":"3333S","volume":"6","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Mol Cancer Ther. 2007;6(12):3333S\u20134S.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"734_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2010.12.014","volume":"73","author":"K Asami","year":"2011","unstructured":"Asami K, Kawahara M, Atagi S, Kawaguchi T, Okishio K. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer. 2011;73(2):211\u20136.","journal-title":"Lung Cancer"},{"issue":"4","key":"734_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11523-017-0497-2","volume":"12","author":"AF Cardona","year":"2017","unstructured":"Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, et al. Acquired resistance to Erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP). Target Oncol. 2017;12(4):513\u201323.","journal-title":"Target Oncol"},{"issue":"3","key":"734_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","volume":"7","author":"QL Pan","year":"2005","unstructured":"Pan QL, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7(3):396\u2013403.","journal-title":"J Mol Diagn."},{"issue":"1","key":"734_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1371\/journal.pmed.0020017","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Wang TY, Riely GJ, Miller VA, Pan QL, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):57\u201361.","journal-title":"PLoS Med"},{"issue":"5","key":"734_CR18","first-page":"692","volume":"9","author":"LM Sholf","year":"2007","unstructured":"Sholf LM, Janne PA, Jackman DM, Joshi VA. Lindeman NI. EGFR kinase domain mutations, but not copy number, predict response to erlotinib and gefitinib in patients with advanced lung adenocarcinoma. J Mol Diagn. 2007;9(5):692.","journal-title":"J Mol Diagn"},{"issue":"12","key":"734_CR19","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/JTO.0000000000000675","volume":"10","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Hida T, Oya Y, Oguri T, Yoshida T, Shimizu J, et al. EGFR mutation impact on definitive concurrent Chemoradiation therapy for inoperable stage III adenocarcinoma. J Thorac Oncol. 2015;10(12):1720\u20135.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"734_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/bjc.2016.456","volume":"116","author":"JJ Yang","year":"2017","unstructured":"Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017;116(5):568\u201374.","journal-title":"Br J Cancer"},{"issue":"2","key":"734_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10147-011-0256-9","volume":"17","author":"S Tetsumoto","year":"2012","unstructured":"Tetsumoto S, Osa A, Kijima T, Minami T, Hirata H, Takahashi R, et al. Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. 2012;17(2):155\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"734_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4161\/cbt.9.8.11881","volume":"9","author":"Y Xu","year":"2010","unstructured":"Xu Y, Liu HY, Chen J, Zhou QH. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther. 2010;9(8):572\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"734_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/CAD.0000000000000268","volume":"26","author":"SRC Normando","year":"2015","unstructured":"Normando SRC, Cruz FM, del Giglio A. Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anti-Cancer Drugs. 2015;26(9):995\u20131003.","journal-title":"Anti-Cancer Drugs"},{"key":"734_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2017.06.007","volume":"110","author":"YC Shen","year":"2017","unstructured":"Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC, Chen WC, et al. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017;110:56\u201362.","journal-title":"Lung Cancer"},{"issue":"11","key":"734_CR25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","volume":"4","author":"T Katayama","year":"2009","unstructured":"Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of Erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to Gefitinib. J Thorac Oncol. 2009;4(11):1415\u20139.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"734_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/JTO.0b013e318169e32a","volume":"3","author":"SG Wu","year":"2008","unstructured":"Wu SG, Shih JY, Yu CJ, Yang PC. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol. 2008;3(4):451\u20132.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"734_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1759-7714.2012.00152.x","volume":"4","author":"SF Yu","year":"2013","unstructured":"Yu SF, Wang Y, Li JL, Hao XZ, Wang B, Wang ZP, et al. Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: a retrospective study. Thorac Cancer. 2013;4(2):109\u201316.","journal-title":"Thorac Cancer."},{"issue":"1","key":"734_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/1759-7714.12049","volume":"5","author":"PY Xing","year":"2014","unstructured":"Xing PY, Li JL, Shi YK, Zhang XR. Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports. Thorac Cancer. 2014;5(1):38\u201342.","journal-title":"Thorac Cancer"},{"issue":"12","key":"734_CR29","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1200\/JCO.2016.68.5842","volume":"35","author":"CH Chang","year":"2017","unstructured":"Chang CH, Lee CH, Wang JY. Gefitinib or Erlotinib for previously treated lung adenocarcinoma: which is superior? J Clin Oncol. 2017;35(12):1374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"734_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"9","key":"734_CR31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","volume":"26","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877\u201383.","journal-title":"Ann Oncol"},{"issue":"4","key":"734_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00280-009-1212-5","volume":"65","author":"T Fukui","year":"2010","unstructured":"Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol. 2010;65(4):803\u20136.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-018-0734-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-018-0734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T16:22:35Z","timestamp":1605457355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-018-0734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1186\/s12890-018-0734-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"25 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The histological samples collected were analysed and the clinical data were retrieved with the endorsement of the Institutional Review Boards and Ethical Review Boards of The Affiliated hospital of Hebei University; The First Affiliated Hospital, Sun Yat-sen University; Jinshan Hospital, Fudan University; The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology. The informed consent from participants was waived by Ethical Review Boards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as no identifying personal information is being published in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"171"}}